Is IONIS PHARMACEUTICALS INC (IONS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 16.9% / 30% | 21.9% / 30% | 0.5% / 30% | 9.76% / 5% | ✗ NOT HALAL |
| DJIM | 16.9% / 33% | 21.9% / 33% | 0.5% / 33% | 9.76% / 5% | ✗ NOT HALAL |
| MSCI | 58.6% / 33% | 76.0% / 33% | 1.9% / 33% | 9.76% / 5% | ✗ NOT HALAL |
| S&P | 16.9% / 33% | 21.9% / 33% | 0.5% / 33% | 9.76% / 5% | ✗ NOT HALAL |
| FTSE | 58.6% / 33% | 76.0% / 33% | 1.9% / 50% | 9.76% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 1.3% | |
| Operating Margin | -105.5% | |
| Net Margin | -40.4% | |
| Return on Equity (ROE) | -70.8% | |
| Return on Assets (ROA) | -7.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$269M |
| Free Cash Flow | -$326M |
| Total Debt | $2.1B |
| Debt-to-Equity | 534.8 |
| Current Ratio | 3.8 |
| Total Assets | $3.5B |
Price & Trading
| Last Close | $74.24 |
| 50-Day MA | $78.84 |
| 200-Day MA | $65.50 |
| Avg Volume | 2.2M |
| Beta | 0.4 |
|
52-Week Range
$23.95
| |
About IONIS PHARMACEUTICALS INC (IONS)
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is IONIS PHARMACEUTICALS INC (IONS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), IONIS PHARMACEUTICALS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is IONIS PHARMACEUTICALS INC's debt ratio?
IONIS PHARMACEUTICALS INC's debt ratio is 16.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 58.6%.
What are IONIS PHARMACEUTICALS INC's key financial metrics?
IONIS PHARMACEUTICALS INC has a market capitalization of $11.9B, and revenue of $944M. The company maintains a gross margin of 1.3% and a net margin of -40.4%. Return on equity stands at -70.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.